Life
Briefing: FDA slams Soon-Shiong and ImmunityBio for making ‘false and misleading’ claims about a drug
Strategic angle: Patrick Soon-Shiong, a controversial figure in the biotech industry, was accused by the FDA of making false and misleading claims about a cancer treatment.
editorial-staff
1 min read
Updated 18 days ago
The FDA has formally accused Patrick Soon-Shiong and his company ImmunityBio of disseminating false and misleading information about a cancer treatment.
This critique raises significant concerns regarding the integrity of clinical claims made by biotech firms, particularly those led by high-profile individuals.
The implications for regulatory compliance and market trust are substantial, highlighting the need for rigorous verification of treatment claims in the oncology sector.